Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial Liu, J., Gaillard, S., Hendrickson, A., Moroney, J., Yeku, O., Diver, E., Gunderson, C., Arend, R., Ratner, E., Samnotra, V., Gupta, D., Evilevitch, L., Wang, S., Wang, P., Tang, J., Bacque, E., Liu, X., Konecny, G. ACADEMIC PRESS INC ELSEVIER SCIENCE. 2021: S17-S18
View details for Web of Science ID 000687070800026